This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... One of the drugs identified using the DRIAD method was Eli Lilly’s Olumiant(baricitinib), which will be investigated in a clinical trial for patients with
35%. Baricitinib is already marketed by Lilly as Olumiant, for the treatment of adults with moderate to severe rheumatoid arthritis in the US.
inhibitor Olumiant (baricitinib) for the novel coronavirus.
In addition to its studies of the COVID-19 targeting antibodies, Lilly is also undertaking clinical development of its JAK inhibitor Olumiant (baricitinib) in combination with Gilead’s remdesivir in patients ... Lilly is also seeking an emergency use
A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and
This includes remdesivir, and Gilead is planning combination studies of the antiviral drug when taken alongside Eli Lilly’s JAK inhibitor Olumiant (baricitinib) and Actemra.
More from news
Approximately 6 fully matching, plus 29 partially matching documents found.
Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...